Event Title

Low Molecular Weight Heparins (LMWH) in the Treatment of Recurrent IVF-ET Failure

Session

Medical, Chemical and Pharmaceutical Sciences

Description

Implantation failure is common in assisted reproductive technology. LMWH can alter the hemostatic response to the controlled ovarian stimulation and modify the risk of thrombosis. It can also modulate many of the fundamental physiological processes required for blastocyst apposition, adherence, and implantation, as well as trophoblast differentiation and invasion due to its similarities with heparan sulfates and has the potential to improve pregnancy rates and outcomes.Our study, represents a retrospective study, which was undertaken during 01 January 2012 – 31 December 2013, in the Department of Gynecology and Obstetrics, at Clinical Hospital in Tetova. The patient demographic: date, month and week of pregnancy; diagnosis; drug details; which include name of the drug, dosage form, dose frequency were recorded.During the period of two years, the number of patiens which received anticoagulation therapy after in viro focundation was 14. The age group with the highest attendance was >35, 6 patients (42.85 %). For 7 patients (50 %), this was their fourth pregnancy. The majority of patients 9 (64.28 %) were treated with Clexane (enoxaparin) 4000 IU anti-Xa in 0.4mL. Despite in vivo and in vitro evidences in favor of the alleged beneficial effect wholesale adoption of this strategy into routine practice will not become a gold standard until further research confirms the presence of such an effect and reveals its exact mechanism of action.

Keywords:

low molecular weight heparins, hypercoagulable state, pregnancy, IVF

Session Chair

Arianit Jakupi

Session Co-Chair

Valon Ejupi

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-437-54-7

Location

Durres, Albania

Start Date

28-10-2017 9:00 AM

End Date

28-10-2017 10:30 AM

DOI

10.33107/ubt-ic.2017.305

This document is currently not available here.

Share

COinS
 
Oct 28th, 9:00 AM Oct 28th, 10:30 AM

Low Molecular Weight Heparins (LMWH) in the Treatment of Recurrent IVF-ET Failure

Durres, Albania

Implantation failure is common in assisted reproductive technology. LMWH can alter the hemostatic response to the controlled ovarian stimulation and modify the risk of thrombosis. It can also modulate many of the fundamental physiological processes required for blastocyst apposition, adherence, and implantation, as well as trophoblast differentiation and invasion due to its similarities with heparan sulfates and has the potential to improve pregnancy rates and outcomes.Our study, represents a retrospective study, which was undertaken during 01 January 2012 – 31 December 2013, in the Department of Gynecology and Obstetrics, at Clinical Hospital in Tetova. The patient demographic: date, month and week of pregnancy; diagnosis; drug details; which include name of the drug, dosage form, dose frequency were recorded.During the period of two years, the number of patiens which received anticoagulation therapy after in viro focundation was 14. The age group with the highest attendance was >35, 6 patients (42.85 %). For 7 patients (50 %), this was their fourth pregnancy. The majority of patients 9 (64.28 %) were treated with Clexane (enoxaparin) 4000 IU anti-Xa in 0.4mL. Despite in vivo and in vitro evidences in favor of the alleged beneficial effect wholesale adoption of this strategy into routine practice will not become a gold standard until further research confirms the presence of such an effect and reveals its exact mechanism of action.